Preclinical studies in other tumor types have shown that dual inhibition of both the PI3K and MEK/ERK pathways with a number of different small molecule kinase inhibitors leads to greater growth inhibition than single pathway inhibition [40–42]. The gene discussed is PIK3CA; the disease is neoplasm.